TEL AVIV, Israel--(BUSINESS WIRE)--Compugen Ltd. (NASDAQ:CGEN) today reported financial results for the third quarter ended September 30, 2007.
“We were pleased to announce during the past quarter the signing of a collaboration agreement with Teva Pharmaceutical Industries covering CGEN-54, a drug candidate for chronic inflammatory diseases, which we initially predicted in silico using our splice variant discovery engine and then validated experimentally,” stated Alex Kotzer, Compugen’s President and CEO. “In addition,” Mr. Kotzer continued, “during the quarter we received the first milestone payments from one of our existing immunoassay diagnostic agreements.”
